Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 5/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979289 | 1.00 | ALDH1A1 (0.51) | ALDH1A1GLATP53CYP3A4TSHR | |
| SCHEMBL8069764 | 1.00 | ALDH1A1 (0.51) | ALDH1A1GLATP53CYP3A4TSHR | |
| SCHEMBL35864709 | 1.00 | ALDH1A1 (0.51) | ALDH1A1GLATP53CYP3A4TSHR | |
| SCHEMBL3266008 | 0.89 | ALDH1A1 (0.53) | ALDH1A1GLATP53CYP3A4TSHR | |
| SCHEMBL3266005 | 0.89 | ALDH1A1 (0.53) | ALDH1A1GLATP53CYP3A4TSHR | |
| SCHEMBL14347222 | 0.89 | ALDH1A1 (0.53) | ALDH1A1GLATP53CYP3A4TSHR | |
| SCHEMBL8068884 | 0.85 | HTR1A (0.43) | HTR1AHTR1DHTR1BNR3C1KDM4E | |
| SCHEMBL729501 | 0.84 | ALDH1A1 (0.65) | ALDH1A1GLATP53CYP3A4TSHR | |
| SCHEMBL21254543 | 0.82 | HTR2A (0.58) | CYP3A4HTR1AHTR1DHTR1B | |
| SCHEMBL9460053 | 0.79 | ALDH1A1 (0.49) | ALDH1A1GLATP53CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622873-B1 | METHOD FOR PRODUCING RAC-1-{4-[2-HYDROXY-3-(5-QUINOLYLOXY)PROPYL]-PIPERAZIN-1-YL}-2,2-DIPHENYLETHAN-1-ONE FUMARATE | BAYER SCHERING PHARMA AG (DE) | 2010-01-13 | — | — | EP | claimed |
| US-7462718-B2 | Process for the production of high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]-piperazin-1-yl}-2,2-diphenylethan-1-one fumarate and high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]piperazin-1-yl}-2,2-diphenylethan-1-one fumarate | SCHERING AG (DE) | 2008-12-09 | — | — | US | claimed |
| EP-1622873-A1 | METHOD FOR PRODUCING THE PUREST RAC-1- {4-[2-HYDROXY-3-(5-QUINOLYLOXY)PROPYL] PIPERAZIN-1-YL} -2,2-DIPHENYLETHAN-1-ONE FUMARATE AND THE PUREST RAC-1-{ 4-[ 2-HYDROXY-3-(5-QUINOLYLOXY)PROPYL]PIPERAZIN-1-YL} -2,2-DIPHENYLETHAN-1-ONE FUMARATE | Schering Aktiengesellschaft (DE) | 2006-02-08 | — | — | EP | claimed |
| US-20050014945-A1 | Process for the production of high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]-piperazin-1-yl}-2,2-diphenylethan-1-one fumarate and high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]piperazin-1-yl}-2,2-diphenylethan-1-one fumarate | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-01-20 | — | — | US | claimed |
| WO-2004099151-A1 | METHOD FOR PRODUCING THE PUREST RAC-1-{4-[2-HYDROXY-3-(5-QUINOLYLOXY)PROPYL] PIPERAZIN-1-YL}-2,2-DIPHENYLETHAN-1-ONE FUMARATE AND THE PUREST RAC-1-{4-[2-HYDROXY-3-(5-QUINOLYLOXY)PROPYL]PIPERAZIN-1-YL}-2,2-DIPHENYLETHAN-1-ONE FUMARATE | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-18 | — | — | WO | claimed |
| EP-1198462-B1 | PROCESS FOR PREPARING A 10,11-METHANODIBENZOSUBERANE DERIVATIVE | LILLY CO ELI (US) | 2004-09-29 | — | — | EP | claimed |
| US-6570016-B1 | Therapy for drug resistant cancer | ELI LILLY AND COMPANY | 2003-05-27 | — | — | US | claimed |
| EP-0695293-B1 | 10,11-METHANODIBENZOSUBERANE DERIVATIVES USED AS CHEMOSENSITIZING AGENTS | SYNTEX INC (US) | 1998-10-14 | — | — | EP | claimed |
| EP-0695293-A1 | 10,11-METHANODIBENZOSUBERANE DERIVATIVES USED AS CHEMOSENSITIZING AGENTS | SYNTEX (U.S.A.) INC. (US) | 1996-02-07 | — | — | EP | claimed |
| WO-1994024107-A1 | 10,11-METHANODIBENZOSUBERANE DERIVATIVES USED AS CHEMOSENSITIZING AGENTS | SYNTEX (U.S.A.) INC. (US) | 1994-10-27 | — | — | WO | claimed |
| JP-4356466-A | — | — | None | — | — | JP | disclosed |
| JP-5043550-A | — | — | None | — | — | JP | disclosed |
| JP-6041105-A | — | — | None | — | — | JP | disclosed |
| JP-4235983-A | — | — | None | — | — | JP | disclosed |
| US-20130331395-A1 | BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-12 | — | — | US | disclosed |
| JP-H04356466-A | NEW QUINOLINE DERIVATIVE AND CARCINOSTATIC AGENT EFFECT ENHANCER CONTAINING THE DERIVATIVE AS ACTIVE INGREDIENT | MITSUI TOATSU CHEM INC | 1992-12-10 | — | — | JP | disclosed |
| JP-H04235983-A | NOVEL QUINOLINE DERIVATIVE AND CARCINOSTATIC EFFECT-ENHANCING AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | MITSUI TOATSU CHEM INC | 1992-08-25 | — | — | JP | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0363212-A2 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-04-11 | — | — | EP | disclosed |
| JP-H00543550-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331395-A1 | BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS | HTR1A, HTR5A, TPH1 | ALDH1A1 66/4885GLA 3840/4885TP53 4762/4885 |
| US-20050014945-A1 | Process for the production of high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]-piperazin-1-yl}-2,2-diphenylethan-1-one fumarate and high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]piperazin-1-yl}-2,2-diphenylethan-1-one fumarate | RAC1, FIS1, RHOT2 | ALDH1A1 1663/4885GLA 3860/4885TP53 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.